Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection

AIDS Patient Care and STDs

Volumn 16, Issue 9, 2002, Pages 405-411

  Romanelli, Frank ^a   Empey, Kerry ^a   Pomeroy, Claire ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; PATIENT COMPLIANCE; PATIENT MONITORING; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANEMIA, MACROCYTIC; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ERYTHROCYTE INDICES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; STAVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0036742740     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729102760330245     Document Type: Article

References (16)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
3. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on Clinical Practice for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. February 4, 2002. Available at: www.hivatis.org.
4. Hect FM. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998;10:57-59.
5. Altice FL, Freidland GH. The era of adherence to HIV therapy. Ann Intern Med 1998;129:504-505.
6. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother 2000;34:703-709.
7. Jennings HJ, Romanelli F. Zidovudine-induced macrocytosis as a marker of antiretroviral adherence in HIV-positive patients. J Am Pharm Assoc 1999;39:150.
8. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
9. Snower DP, Weil SC. Changing etiology of macrocytosis; zidovudine as a frequent causative factor. Am J Clin Pathol 1993;99:57-60.
10. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-949.
11. D'Aquila R, Swanstrom R, Resistance. In: Larder B, Richman D, Vella S, eds. HIV Resistance and Implications for Therapy. Atlanta, GA: Medicom Inc.; 1998: 2.1.1-2.8.
12. Duong M, Piroth L, Peytavin G, et al. Value of plasma self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response. Clin Infect Dis 2001;33:386-392.
13. Eyer-Silva WA, Arabe J, Pinto JF, et al. Macrocytosis in patients on stavudine. Scand J Infect Dis 2001;33:239-240.
14. Geene D, Sudre P, Anward D. Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss Cohort Study. J Infect 2000;40:160-163.
15. Walker RE, Parker RI, Kovacs JA, et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and kaposi sarcoma treated with zidovudine. Ann Intern Med 1988;108:372-376.
16. Piscitelli SC. The limited value of therapeutic drug monitoring in HIV infection. Medscape HIV/AIDS 1999;5(4):1-4.